EP1633316A4 - ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS - Google Patents

ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS

Info

Publication number
EP1633316A4
EP1633316A4 EP04775943A EP04775943A EP1633316A4 EP 1633316 A4 EP1633316 A4 EP 1633316A4 EP 04775943 A EP04775943 A EP 04775943A EP 04775943 A EP04775943 A EP 04775943A EP 1633316 A4 EP1633316 A4 EP 1633316A4
Authority
EP
European Patent Office
Prior art keywords
antibodies binding
trail receptors
binding immunospecifically
immunospecifically
trail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04775943A
Other languages
German (de)
French (fr)
Other versions
EP1633316A2 (en
Inventor
Theodora Salcedo
Craig A Rosen
Vivian R Albert
Robin Humphreys
Tristan John Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1633316A2 publication Critical patent/EP1633316A2/en
Publication of EP1633316A4 publication Critical patent/EP1633316A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP04775943A 2003-05-06 2004-05-05 ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS Withdrawn EP1633316A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46809203P 2003-05-06 2003-05-06
US49514003P 2003-08-15 2003-08-15
PCT/US2004/013900 WO2005016236A2 (en) 2003-05-06 2004-05-05 Antibodies that immunospecifically bind to trail receptors

Publications (2)

Publication Number Publication Date
EP1633316A2 EP1633316A2 (en) 2006-03-15
EP1633316A4 true EP1633316A4 (en) 2008-04-02

Family

ID=34197757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04775943A Withdrawn EP1633316A4 (en) 2003-05-06 2004-05-05 ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS

Country Status (3)

Country Link
EP (1) EP1633316A4 (en)
CA (1) CA2524737A1 (en)
WO (1) WO2005016236A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
PT2360255E (en) 2005-03-25 2015-04-08 Nat Res Council Canada Method for isolation of soluble polypeptides
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
RU2442793C2 (en) 2005-11-30 2012-02-20 Эбботт Лэборетриз ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
KR20150127202A (en) 2013-03-14 2015-11-16 바이엘 헬스케어 엘엘씨 Monoclonal antibodies against antithrombin beta complexed with heparin
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
CN120693395A (en) * 2022-10-20 2025-09-23 北京三诺佳邑生物技术有限责任公司 Antibody combinations and bispecific antibodies that specifically bind to TRAIL or FasL

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150985A1 (en) * 1997-05-15 2002-10-17 Genentech, Inc. Apo-2 receptor
WO2002097033A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2003054216A2 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150985A1 (en) * 1997-05-15 2002-10-17 Genentech, Inc. Apo-2 receptor
WO2002097033A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
WO2003054216A2 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
WO2005016236A3 (en) 2007-06-14
EP1633316A2 (en) 2006-03-15
WO2005016236A2 (en) 2005-02-24
CA2524737A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
EP1465925A4 (en) ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS
EP1572874A4 (en) ANTIBODIES BINDING IMMUNOSPECIFICALLY TO TRAIL RECEPTORS
CY2022005I2 (en) OPTIMIZED ANTIBODIES TARGETING CD19
DK2177537T3 (en) Antibodies to MAdCAM
CY2017039I1 (en) HIGH-AFFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR
RU2426741C3 (en) ANTAGONISTIC ANTIBODIES TO IL-17
IL191340A (en) Human monoclonal antibodies to o8e
IL189788A0 (en) Human monoclonal antibodies to cd70
IS3021B (en) Antibodies to M-CSF
GB0417384D0 (en) Antibodies to c-met
PL2489364T3 (en) Monomethylvaline compounds conjugated to antibodies
EP1572874A3 (en) Antibodies that immunospecifically bind to trail receptors
DK1737891T3 (en) ANTI-P-selectin ANTIBODIES
EP1768999A4 (en) ANTIBODY BINDING TO B7-DC
PL372662A1 (en) Antibodies to alfav beta6
DE602004022805D1 (en) QUINUCLIDIN DERIVATIVES BINDING TO MUSCARIN M3 RECEPTORS
DK1794586T3 (en) Monoclonal antibodies to progastrin
FR14C0029I1 (en) STABILIZED PROSTAGLANDIN COMPOSITION
ZA200802641B (en) Human monoclonal antibodies to CD70
NL1026829A1 (en) Modified human IGF-1R antibodies.
EP1675606A4 (en) PEPTIDES AND COMPOUNDS BINDING TO THROMBOPOIETINE RECEPTORS
AU2003218456A8 (en) Antibodies that specifically bind to gmad
DK1817343T3 (en) Human monoclonal antibodies to human IL-4
AU2003259835A8 (en) Antibodies that immunospecifically bind to trail receptors
EP1826218A4 (en) ANTI-BAFF HUMAN ANTIBODIES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051202

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/00 20060101ALI20070727BHEP

Ipc: A61K 39/395 20060101ALI20070727BHEP

Ipc: C12N 5/24 20060101ALI20070727BHEP

Ipc: C07K 16/00 20060101AFI20070727BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080228

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20080222BHEP

Ipc: A61P 37/00 20060101ALI20080222BHEP

Ipc: A61P 35/00 20060101ALI20080222BHEP

Ipc: A61K 39/395 20060101ALI20080222BHEP

Ipc: C12N 5/24 20060101ALI20080222BHEP

Ipc: C07K 16/28 20060101AFI20080222BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080515